Comparative effects of 8-week combined resistance exercise training and alternate-day calorie restriction on soluble epidermal growth factor receptor (sEGFR) and adipsin in obese men [0.03%]
联合抗阻运动和间歇性交替日限食对肥胖男性可溶型表皮生长因子受体（sEGFR）和adipsin的影响研究
Yousif Hikmat,Alireza Safarzade,Hamid Alizadeh
Yousif Hikmat
This study investigated the combined effects of resistance exercise training (RET) and alternate-day calorie restriction (ADCR) on body composition, insulin resistance (IR), insulin resistance-related biomarkers (adipokine adipsin and hepat...
Randomized Controlled Trial
Growth factors (Chur, Switzerland). 2024 Aug;42(3):111-119. DOI:10.1080/08977194.2024.2378889 2024
VEGF-B is involved in diabetic peripheral neuropathy in patients with type 2 diabetes [0.03%]
血管内皮生长因子B参与2型糖尿病患者的糖尿病外周神经病变
Ruonan Zhou,Yingying Xue,Ziwei Zhu et al.
Ruonan Zhou et al.
Aims: This study aims to explore the potential role of vascular endothelial growth factor-B (VEGF-B) in the pathogenesis of diabetic peripheral neuropathy (DPN). The expression of VEGFRs were reanalysed by using gene arrays of peripheral ne...
FOXN2, identified as a novel biomarker in serum, modulates the transforming growth factor-beta signaling pathway through its interaction with partitioning defective 6 homolog alpha, contributing to the pathogenesis of gastric cancer [0.03%]
新型胃癌血清生物标志物FOXN2通过与PARDA相互作用调节转化生长因子-β信号通路促进胃癌发生发展
Liang Li,XueFeng Sun,Mei Zhang et al.
Liang Li et al.
Background and objective: Dysregulated expression of Forkhead Box N2 (FOXN2) has been detected in various cancer types. However, the underlying mechanisms by which FOXN2 contributes to the onset and progression of gastric...
GALNT6, GALNT14, and Gal-3 in association with GDF-15 promotes drug resistance and stemness of breast cancer via β-catenin axis [0.03%]
通过β-catenin轴,GALNT6、GALNT14和Gal-3与GDF-15相互作用促进乳腺癌的耐药性和干细胞特性
Ashita Gadwal,Purvi Purohit,Manoj Khokhar et al.
Ashita Gadwal et al.
N-acetylgalactosaminyltransferases (GALNTs) are a polypeptide responsible for aberrant glycosylation in breast cancer (BC), but the mechanism is unclear. In this study, expression levels of GALNT6, GALNT14, and Gal-3 were assessed in BC, an...
Interleukin-3 production by basal-like breast cancer cells is associated with poor prognosis [0.03%]
基底样乳腺癌细胞产生白介素3与预后不良有关
Emma J Thompson,Samantha Escarbe,Denis Tvorogov et al.
Emma J Thompson et al.
Breast cancer represents a collection of pathologies with different molecular subtypes, histopathology, risk factors, clinical behavior, and responses to treatment. "Basal-like" breast cancers predominantly lack the receptors for estrogen a...
PLA2G2D fosters angiogenesis in non-small cell lung cancer through aerobic glycolysis [0.03%]
PLA2G2D通过需氧糖酵解促进非小细胞肺癌的血管生成
Huaizhong Zhang,Keng Chen,Yongqing Zhou et al.
Huaizhong Zhang et al.
Non-small cell lung cancer (NSCLC) stands prominent among the prevailing and formidable oncological entities. The immune and metabolic-related molecule Phospholipase A2, group IID (PLA2G2D) exerts promotional effects on tumor progression. H...
Evaluation of the effect of injectable platelet-rich fibrin (i-PRF) in wound healing and growth factor release in rats: a split-mouth study [0.03%]
评价可注射富血小板纤维蛋白(i-PRF)对大鼠创面愈合及生长因子释放的影响：一种半口对照研究方法
Aysan Lektemur Alpan,Gizem Torumtay Cin,Alper Kızıldağ et al.
Aysan Lektemur Alpan et al.
This experimental study aimed to evaluate the effects of injectable platelet-rich fibrin (i-PRF) on mucosal healing and the release of growth factors in rats. 40 rats were used; i-PRF was administered in the right buccal area while saline w...
The effects of 12 weeks of high-intensity interval training and moderate-intensity continuous training on FGF21, irisin, and myostatin in men with type 2 diabetes mellitus [0.03%]
高强度间歇训练和中等强度持续训练对2型糖尿病患者FGF21、irisin和肌生长抑制素的影响
Simin Riahy
Simin Riahy
This study investigated the influence of a 12-week high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) on irisin, fibroblast growth factor 21 (FGF21), and myostatin (MSTN) among men with type 2 diabetes...
Randomized Controlled Trial
Growth factors (Chur, Switzerland). 2024 Feb;42(1):24-35. DOI:10.1080/08977194.2023.2279163 2024